B · Normal
[Zhifei Bio: Nasal spray recombinant RSV vaccine approved for clinical trials] On October 23, Zhifei Bio (300122.SZ) announced that the nasal spray recombinant respiratory syncytial virus vaccine developed by the company's wholly-owned subsidiary Zhifei Lvzhu has been approved for clinical trials by the State Food and Drug Administration, and it has agreed to conduct clinical trials to prevent diseases related to RSV infection. As of the announcement date, no RSV vaccine has been approved for marketing in China. This product uses nasal spray mucosal immunization technology and is expected to provide a new non-invasive prevention option for high-risk groups.
A-share announcement express 🕐 2026-10-23 16:02
#clinical trial #Virus #vaccine #A-share announcement express
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Zhefu Holdings: Net profit in the first three quarters increased by 124.91% yea 10-23 16:30 [Espressif Technology: Net profit in the first three quarters increased by 46.76 10-23 16:24 [2-connected board Zhengyu Industrial: Flexible tactile products are still in th 10-23 16:18 [Ultrapure Application Materials: Net profit in the first three quarters increas 10-23 16:08 [Kodali: Net profit in the first three quarters increased by 28.87% year-on-year 10-23 16:06 [Wavelength Optoelectronics: Net profit in the first three quarters increased by 10-23 15:54

Comments

0/500
Captcha (click to refresh)
No comments yet